Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Erschienen in:
Aufgaben und Organisation von Neuro-Intensivstationen Kapitel lesen Erstes Kapitel lesen

2015 | OriginalPaper | Buchkapitel

37. Neuromuskuläre Erkrankungen

verfasst von : Wolfgang Müllges, Prof. Dr., Ralf Gold, Prof. Dr., Hans-Christian Hansen, Prof. Dr., Martin Anetseder, Prof. Dr., Thomas Metterlein, PD Dr., Clemens R. Müller, Prof. Dr. rer. nat., Ernst Hund, Prof. Dr., Martin Winterholler, PD Dr.

Erschienen in: NeuroIntensiv

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

In diesem Kapitel werden im Schwerpunkt entzündliche bzw. autoimmune Erkrankungen des neuromuskulären Systems sowie spezifische Erkrankungen behandelt. Zu den ersteren gehören das Guillain-Barré-Syndrom (GBS; Acute Inflammatory Demyelinating Polyneuroradiculitis, AIDP) als häufigste Variante der schweren akuten entzündlichen Polyradikuloneuritiden und die Myasthenia gravis, vorwiegend in der intensivpflichtigen Maximalausprägung. Rhabdomyolyse, malignes neuroleptisches Syndrom, maligne Hyperthermie, und Critical- Illness-Polyneuropathie und -myopathie sind typische Erkrankungen, die eine (neuro)intensivmedizinische Versorgung bedingen. Die Langzeitprognose ist nach überstandener Akutphase sehr gut, obwohl CIP und CIM eine häufige Ursache für eine notwendige Langzeitbeatmung sind. Auch wenn Botulismus und Tetanus eher selten anzutreffen sind, stellen sie wichtige neurointensivmedizinische Erkrankungen dar, die früh erkannt und behandelt werden müssen.
Literatur
1.
Baxter R, Bakshi N, Fireman B, Lewis E, Ray P, Vellozzi C, Klein NP (2013) Lack of association of Guillain-Barré syndrome with vaccinations. Clin Infect Dis 57:197–202PubMedCrossRef
2.
Bernsen RA, deJager AE, Kuijer W et al (2010) Psychosocial dysfunction in the first year after Guillain-Barré syndrome. Muscle Nerve 41:533–539PubMedCrossRef
3.
Buchwald B, Ahangari R, Weishaupt A et al (2002) Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome. Ann Neurol 51:673–680PubMedCrossRef
4.
Chang KH, Chuang TJ, Lyu RK, Wu YR, Chang HS et al (2012) Identification of gene networks and pathways associated with Guillain-Barré syndrome. PlOS One 7:e295065CrossRef
5.
Dionne A, Nicolle MW, Hahn AF (2010) Clinical and electrophysiological parameters distinguishing acute-onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy. Muscle Nerve 41:202–207PubMed
6.
Dutch Guillain-Barre Study Group (1994) Treatment of Guillain-Barre-Syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. Ann Neurol 35:749–752CrossRef
7.
Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC (2014) Diagnosis of Guillain Barré syndrome and validatioon of Brighton criteria. Brain 137:33–43PubMedCrossRef
8.
French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome (1997) Appropriate number of plasma exchanges in Guillain-Barre syndrome. Ann Neurol 41:298–306CrossRef
9.
Gold R, Dalakas MC, Toyka KV (2003) Immunotherapy in autoimmune neuromuscular disorders. Lancet Neurol 2:22–32PubMedCrossRef
10.
Gold R, Stangel M, Dalakas MC (2007) Drug Insight: the use of intravenous immunoglobulin in neurology – therapeutic considerations and practical issues. Nat Clin Prac Neurol 3:36–44CrossRef
11.
Gonzalez-Suarez I, Sanz-Gallego I, der Rivera FJR, Arpa J (2013) Guillain-Barré syndrome: natural history and prognostic factors. BMC Neurology 13:95–99PubMedPubMedCentralCrossRef
12.
Guillain-Barre Syndrome Steroid Trial Group (1993) Double-blind trial of intravenous methylprednisolone in Guillain-Barre syndrome. Lancet 341:586–590
13.
Hadden RD, Cornblath DR, Hughes RA et al (1998) Electrophysiological classification of Guillain-Barre syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Ann Neurol 44:780–788PubMedCrossRef
14.
Heritier F, Rahm F, Pasche P et al (1994) Sniff nasal inspiratory pressure. A noninvasive assessment of inspiratory muscle strength. Am J Respir Crit Care Med 150:1678–1683PubMedCrossRef
15.
Ho TW, Hsieh ST, Nachamkin I et al (1997) Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection [see comments]. Neurology 48:717–724PubMedCrossRef
16.
17.
Kaida K, Kasunoki S (2010) Antibodies to gangliosides andd gangliosid complexes in Guillain-Barré syndrome and Fisher syndrome: mini-review. J Neuroimmunol 233:5–12CrossRef
18.
Kerasnoudis A, Pitarokoili K, Behrendt V, Gold R, Yoon MS (2014) Nerve ultrasound score in distinguishing chronic from acute inflammatory demyelinating polyneuropathy. Clin Neurophysiol 125:635–641PubMedCrossRef
19.
Khan F, Amatya B (2012) Rehabilitation interventions in patients with acute demyelinating inflammatory polyneuropathy: a systematic review. Eur J Rehabil Med 48:507–522
20.
Kuitwaard K, de Gelder J, Tio-Gillen AP et al (2009) Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol 66:597–603PubMedCrossRef
21.
Kuwabara S, Yuki N (2013) Axonal Guillain-Barré syndrome: concepts and controversies. Lancet Neurol 12:1180–1188PubMedCrossRef
22.
Kwong JC, Vasa PP, Campitelli MA, Hawken S, Wilson K et al (2013) Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters. Lancet Infect Dis 13:769–776PubMedCrossRef
23.
Lehmann HC, Hughes RAC, Kieseier BC, Hartung HP (2012) Recent developments and future directions in Guillain-Barré syndrome. J Periph Nerv Syst 17:57–70CrossRef
24.
Levine S, Nguyen T, Taylor N et al (2008) Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans. New Engl J Med 358:1327–1328PubMedCrossRef
25.
Liu J, Wang LN, McNicol ED (2013) Pharmacological treatment for pain in Guillain-Barré syndrome. Cochrane Database Syst Rev 10:CD009950PubMed
26.
McKhann GM, Cornblath DR, Griffin JW et al (1993) Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 33:333–342PubMedCrossRef
27.
Mori K, Hattori N, Sugiura M et al (2002) Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS. Neurology 58:979–982PubMedCrossRef
28.
Mukerji S, Aloka F, Farooq MU et al (2009) Cardiovascular complications of the Guillain-Barré syndrome. Am J Cardiol 104:1452–1455PubMedCrossRef
29.
Müllges W (2013) Respiratorentwöhnung. Definition und klinischer Kontext aus Sicht der Neurologie. AINS 48:616–621PubMed
30.
Müllges W, Toyka KV (1997) Akute Muskelschwäche – Differentialdiagnose und Therapie neuromuskulärer Krankheiten. Intensivmedizin und Notfallmedizin 34:110–123CrossRef
31.
Müllges W, Stoll G (2009) Intensivmedizinische Probleme bei neuromuskulärern Krankheiten. Intensivmed up2date 5:209–228CrossRef
32.
Müllges W, Stoll G (2010) Akuttherapie des Guillain-Barré-Syndroms und der Myasthenen Krise. Akt Neurol 37:474–484CrossRef
33.
Needham DM (2008) Mobilizing patients in the intensive care unit: improving neuromuscular weakness and physical function. JAMA 300:1685–1690PubMedCrossRef
34.
35.
Patwa HS, Chaudry V, Katzberg H, Rae-Grant AD, So YT (2012) Evidence-based guideline: intravenouus immunoglobulin in the treatment of neuromuscular disorders. Neurology 78:1009–1015PubMedCrossRef
36.
Paul BS, Bhatia R, Prasad K, Padma MV, Tripathi M, Singh MB (2012) Clinical predictors of mechanical ventilation in Guillain-Barré syndrome. Neurol India 60:150–153PubMedCrossRef
37.
PSGBS study group (1997) Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 349:225–230CrossRef
38.
Rajabally YA, Uncini A (2012) Outcome and its predictors in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatr 83:711–718PubMedCrossRef
39.
Raphael JC, Chevret S, Harboun M et al (2001) Intravenous immune globulins in patients with Guillain-Barre syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 71:235–238PubMedPubMedCentralCrossRef
40.
Raphael JC, Chveret S, Hughes RA, Annane D (2012) Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 11(7):CD001798
41.
Rinaldi S (2013) Update on Guillain-Barré syndrome. J Periph Nerv Syst 18:99–112CrossRef
42.
Ruts L, Drenthen J, Jongen JLM, Hop WCJ, Visser GH et al (2010) Pain in Guillain-Barré syndrome: a long-term follow-up study. Neurology 75:1439–1447PubMedCrossRef
43.
Salmon DA, Proschan M, Forshee R, Garguillo P, Bleser W et al (2013) Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet 381:1461–1468PubMedCrossRef
44.
Teener JW (2012) Miller-Fisher´s syndrome. Semin Neurol 32:512–516PubMed
45.
van den Berg B, Bunschoten C, van Doorn PA, Jacobs BC (2013) Mortality in Guillain-Barré syndrome. Neurology 80:1650–1654PubMedCrossRef
46.
van Koningsveld R, Schmitz PIM, van der Meche FGA et al (2004) Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet 363:192–196PubMedCrossRef
47.
Vucic S, Kieman MC, Cornblath DR (2009) Guillain-Barré syndrome: an update. J Clin Neurosci 16:733–741PubMedCrossRef
48.
Wakerley BR, Yuki N (2013) Infectious and noninfectious triggers in Guillain-Barré syndrome. Expert Rev Clin Immunol 9:627–639PubMedCrossRef
49.
Wakerley BR, Yuki N (2014) Pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. J Neurol Neurosurg Psychiatr 85:339–344PubMedCrossRef
50.
Weiß H, Lauter V, Müllges W et al (2002) Psychotic symptoms and emotional distress in patients suffering from acute Guillain-Barré syndrome. Eur Neurol 47:74–78PubMedCrossRef
51.
Alterman I, Sidi A, Azamfirei L, Copotoiu S, Ezri T (2007) Rhabdomyolysis: another complication after prolonged surgery. Journal of Clinical Anesthesia 19:64–66PubMedCrossRef
52.
Balcarek P, Frosch KH, Quintel M, Stürmer KH (2005) Systemisches Kapillarlecksyndrom als Ursache eines Kompartmentsyndroms beider Unterschenkel und eines Unterarms. Unfallchirurg 108:770–776PubMedCrossRef
53.
54.
Hansen HC (2013) Bewusstseinsstörungen und Enzephalopathien. Springer, HeidelbergCrossRef
55.
Hensel M, Böhler K, Matrnitz R, Binder C, von Brevern M (2010) Intensivmedizinisches Management des malignen neuroleptischen Syndroms. Anästhesiol Intensivmed Notfallmed Schmerzther 45:448–455PubMedCrossRef
56.
Klockgether T, Weller M, Haarmeir T, Kaskas B, Maier G, Dichgans J (1997) Gluteal compartment syndrome due to rhabdomyolysis after heroin abuse. Neurology 48:275–276PubMedCrossRef
57.
Köller H, Neuhaus O, Schroeter M, Hartung HP (2005) Myopathien unter der Therapie mit Lipidsenkern. Nervenarzt 76:212–217PubMedCrossRef
58.
Maddison P (2002) Acute rhabdomyolysis and brachial plexopathy following alcohol ingestion. Muscle Nerve 25:283–285PubMedCrossRef
59.
Perry PJ, Wilborn CA (2012) Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management. Ann Clin Psychiatry 24:155–162PubMed
60.
Quinlivan R, Jungbluth H (2012) Myopathic causes of exercise intolerance with rhabdomyolysis. Developmental Medicine and Child Neurology 54:886–891PubMedCrossRef
61.
Ramsay DA, Zochodne DW, Robertson DM, Nag S, Ludwin SK (1993) A syndrome of acute severe muscle necrosis in intensive care unit patients. J Neuropathol Exp Neurol 52:387–398PubMedCrossRef
62.
Rich MM, Teener JW, Raps EC, Schotland MD, Bird SJ (1996) Muscle is electrically inexcitable in acute quadriplegic myopathy. Neurology 46:731–736PubMedCrossRef
63.
Schwab S, Krieger D, Müllges W (Hrsg) (1999) Neurologische Intensivmedizin. Springer, Berlin
64.
Winkler G, Beese M (1998) Rhabdomyolysen. In: Beese M, Winkler G (Hrsg) MRT der Muskulatur. Thieme, Stuttgart, S 247–256
65.
Zaccheo MM, Bucher DH (2008) Propofol Infusion Syndrome. Crit Care Nurse 28:18–27PubMed
66.
67.
Anetseder M, Hager M, Müller CR, Roewer N (2002) Diagnosis of susceptibility to malignant hyperthermia by use of a metabolic test. Lancet 359:1579–1580PubMedCrossRef
68.
Anetseder M, Hartung E, Klepper S, Reichmann H (1994) Gasoline vapors induce severe rhabdomyolysis. Neurology 44:2393–2395PubMedCrossRef
69.
Anetseder M, Roewer N (2008) Maligne Hyperthermie. In: Rossaint R, Werner C, Zwissler B (Hrsg) Die Anästhesiologie, S 1314–1323CrossRef
70.
Baur CP, Schara U, Schlecht R, Georgieff M, Lehmann-Horn F (2002) Anesthesia in neuromuscular disorders. Part 2: Specific disorders. Anästhesiologie Intensivmedizin Notfallmedizin Schmerztherapie 37:125–137CrossRef
71.
Baur CP, Schlecht R, Jurkat-Rott K, Georgieff M, Lehmann-Horn F (2002) Anesthesia in neuromuscular disorders. Part 1: Introduction. Anästhesiologie Intensivmedizin Notfallmedizin Schmerztherapie 37:77–83CrossRef
72.
Beschluss des Engeren Präsidiums der DGAI vom 11.04.2008 (2008) Empfehlung zur Therapie der malignen Hyperthermie. Anästh Intensivmed 49: 483–488
73.
Denborough MA, Lovell RRH (1960) Anaesthetic deaths in a family. Lancet 2:45–50CrossRef
74.
Duke AM, Hopkins PM, Halsall PJ, Steele DS (2006) Mg2+ dependence of Ca2+ release from the sarcoplasmic reticulum induced by sevoflurane or halothane in skeletal muscle from humans susceptible to malignant hyperthermia. Br J Anaesth 97:320–328PubMedCrossRef
75.
Girard T, Cavagna D, Padovan E, Spagnoli G, Urwyler A, Zorzato F, Treves S (2001) B-lymphocytes from malignant hyperthermia-susceptible patients have an increased sensitivity to skeletal muscle by ryanodine receptor activators. J Biol Chem 276:48077–48082PubMed
76.
Glahn KPE, Ellis FR, Halsall PJ, Müller CR, Snoeck MMJ, Urwyler A, Wappler F (2010) Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. B J Anaesth 105:417–420CrossRef
77.
Gronert GA, Antognini JF, Pessah (2000) Malignant Hyperthermia. In: Miller RD (Hrsg) Anesthesia. Elsevier, Philadelphia, S 1033–1052
78.
Hüttemann K, Nowe T, Köhrmann M, Anetseder M, Schellinger PD (2009) Maligne Hyperthermie und deren Differenzialdiagnosen. Fortschr Neurol Psychiat 77:203–211PubMedCrossRef
79.
Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB (2010) Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg 110:498–507PubMedCrossRef
80.
Leong P, MacLennan DH (1998) A 37-amino acid sequence in the skeletal muscle ryanodine receptor interacts with the cytoplasmic loop between domains II and III in the skeletal muscle dihydropyridine receptor. J Biol Chem 273:7791–7794PubMedCrossRef
81.
Litman RS, Flood CD, Kaplan RF, Kim YL, Tobin JR (2008) Postoperative malignant hyperthermia: an analysis of cases from the North American Malignant Hyperthermia Registry. Anesthesiology 109:825–829PubMedCrossRef
82.
McCarthy TV, Healy JM, Heffron JJ et al (1990) Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature 343:562–564PubMedCrossRef
83.
Monnier N, Procaccio V, Stieglitz P, Lunardi J (1997) Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet 60:1316–1325PubMedPubMedCentralCrossRef
84.
Monnier N, Krivosic-Horber R, Payen JF et al (2002) Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology 97:1067–1074PubMedCrossRef
85.
Ording H, Brancadoro V, Cozzolino S et al (1997) In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand 41:955–966PubMedCrossRef
86.
Parnes J, Bandschapp O, Girard T (2009) The Myotonias and Susceptibility to Malignant Hyperthermia. Anesth Analg 109:1054–1064CrossRef
87.
Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P (2006) Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat 27:977–989PubMedCrossRef
88.
Robinson RL, Anetseder MJ, Brancadoro V et al (2003) Recent advances in the diagnosis of malignant hyperthermia susceptibility: How confident can we be of genetic testing? Eur J Hum Genet 11:342–348PubMedCrossRef
89.
90.
Rossaint R, Werner C, Zwissler B (2008) Die Anästhesiologie, 2. Aufl. Springer, Berlin Heidelberg New YorkCrossRef
91.
Rüffert H, Wehner M, Deutrich C, Olthoff D (2007) Malignant hyperthermia. The ugly. Anaesthesist 56:923–929PubMedCrossRef
92.
Schuster F, Müller R, Hartung E, Roewer N, Anetseder M (2005) Inhibition of sarcoplasmic Ca2+-ATPase increases caffeine- and halothane-induced contractures in muscle bundles of malignant hyperthermia susceptible and healthy individuals. BMC Anesthesiol 5:8PubMedPubMedCentralCrossRef
93.
Schuster F, Scholl H, Hager M, Müller R, Roewer N, Anetseder M (2006) The dose-response relationship and regional distribution of lactate after intramuscular injection of halothane and caffeine in malignant hyperthermia-susceptible pigs. Anesth Analg 102:468–472PubMedCrossRef
94.
Stowell K et al (2014) DNA testing for malignant hyperthermia: the reality and the dream. Anesth Analg 118:397–406PubMedCrossRef
95.
The European Malignant Hyperpyrexia Group (1984) A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 56:1267–1269CrossRef
96.
Urwyler A, Deufel T, McCarthy T, West S (2001) Guidelines for the detection of malignant hyperthermia susceptibility. Br J Anaesth 86:283–287 (for the European Malignant Hyperthermia Group)PubMedCrossRef
97.
Wappler F, Fiege M, Steinfath M, Agarwal K, Scholz J, Singh S, Matschke J, Schulte Am Esch J (2001) Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis. Anesthesiology 94:95–100PubMedCrossRef
98.
99.
Annane D, Sébille V, Charpentier C et al (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862–871PubMedCrossRef
100.
Batt J, dos Santos CC, Cameron JI, Herridge MS (2013) Intensive care unit-acquired weakness: clinical phenotypes and molecular mechanisms. Am J Respir Crit Care Med 187:238–246PubMedCrossRef
101.
Bednarik J, Lukas Z, Vondracek P (2003) Critical illness polyneuromyopathy: the electrophysiological components of a complex entity. Int Care Med 29:1505–1514CrossRef
102.
Blobner M, Kochs E, Fink H et al (1999) Pharmacokinetics and pharmacodynamics of vecuronium in rats with systemic inflammatory response syndrome: treatment with NG-monomethyl-L-arginine. Anesthesiology 91:999–1005PubMedCrossRef
103.
Bolton CF (1996) Sepsis and the systemic inflammatory response syndrome: neuromuscular manifestations. Crit Care Med 24:1408–1416PubMedCrossRef
104.
Danon MJ, Carpenter S (1991) Myopathy with thick filament (myosin) loss following prolonged paralysis with vecuronium during steroid treatment. Muscle Nerve 14:1131–1139PubMedCrossRef
105.
De Jonghe B, Sharshar T, Lefaucheur JP et al (2002) Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA 288:2859–2867PubMedCrossRef
106.
De Letter MACJ, Schmitz PIM, Visser LH et al (2001) Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med 29:2281–2286PubMedCrossRef
107.
De Letter MACJ, van Doorn PA, Savelkoul HFJ et al (2000) Critical illness polyneuropathy and myopathy (CIPNM): evidence for local immune activation by cytokine-expression in the muscle tissue. J Neuroimmunol 106:206–213PubMedCrossRef
108.
Di Giovanni S, Molon A, Broccolini A et al (2004) Constitutive activation of MAPK cascade in acute quadriplegic myopathy. Ann Neurol 55:195–206PubMedCrossRef
109.
Dos Santos CC, Batt J (2012) ICU-acquired weakness: mechanisms of disability. Curr Opin Crit Care 18:509–517PubMedCrossRef
110.
Fenzi F, Latronico N, Refatti N, Rizzuto N (2003) Enhanced expression of E-selectin on the vascular endothelium of peripheral nerve in critically ill patients with neuromuscular disorders. Acta Neuropathol (Berl) 106:75–82
111.
Fletcher SN, Kennedy DD, Ghosh IR et al (2003) Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. Crit Care Med 31:1012–1016PubMedCrossRef
112.
Friedrich O, Hund E, Weber C et al (2004) Critical illness myopathy serum fractions affect membrane excitability and intracellular calcium release in mammalian skeletal muscle. J Neurol 251:53–65PubMedCrossRef
113.
Garnacho-Montero J, Amaya-Villar R, Garcia-Garmendia JL et al (2005) Effect of critical illness polyneuropathy on the withdrawal from mechanical ventilation and the length of stay in septic patients. Crit Care Med 33:349–354PubMedCrossRef
114.
Geller TJ, Kaiboriboon K, Fenton GA et al (2001) Vecuronium-associated axonal motor neuropathy: a variant of critical illness polyneuropathy? Neuromuscul Disord 11:579–582PubMedCrossRef
115.
Haeseler G, Foadi N, Wiegand E et al (2008) Endotoxin reduces availability of voltage-gated human skeletal muscle sodium channels at depolarized membrane potentials. Crit Care Med 36:1239–1247PubMedCrossRef
116.
Herridge MS, Cheung AM, Tansey CM et al (2003) One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 348:683–693PubMedCrossRef
117.
Hund E (2001) Neurological complications of sepsis: critical illness polyneuropathy and myopathy. J Neurol 248:929–934PubMedCrossRef
118.
Hund E, Fogel W, Krieger D et al (1996) Critical illness polyneuropathy: clinical findings and outcomes of a frequent cause of neuromuscular weaning failure. Crit Care Med 24:1328–1333PubMedCrossRef
119.
Hund E, Herkert M, Becker C-M et al (1996) A humoral neurotoxic factor in sera of patients with critical illness polyneuropathy (abstr.). Ann Neurol 40:539
120.
Khan J, Harrison TB, Rich MM et al (2006) Early development of critical illness myopathy and neuropathy in patients with severe sepsis. Neurology 67:1421–1425PubMedCrossRef
121.
Kress JP, Hall JB (2014) ICU-acquired weakness and recovery from critical illness. N Engl J Med 370:1626–1635PubMedCrossRef
122.
Kukreti V, Shamim M, Khilnani P (2014) Intensive care unit acquired weakness in children: Critical illness polyneuropathy and myopathy. Indian J Crit Care Med 18:95–101PubMedPubMedCentralCrossRef
123.
Latronico N (2003) Neuromuscular alterations in the critically ill patient: critical illness myopathy, critical illness neuropathy, or both? Intensive Care Med 29:1411–1413PubMedCrossRef
124.
Latronico N, Bolton CF (2011) Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. Lancet Neurol 10:931–941PubMedCrossRef
125.
Latronico N, Bertolini G, Guarneri B et al (2007) Simplified electrophysiological evaluation of peripheral nerves in critically ill patients: the Italian multi-centre CRIMYNE study. Crit Care 11:R11PubMedPubMedCentralCrossRef
126.
Lewis KS, Rothenberg DM (1999) Neuromuscular blockade in the intensive care unit. Am J Health Syst Pharm 56:72–75PubMed
127.
Maramattom BV, Wijdicks EFM (2006) Acute neuromuscular weakness in the intensive care unit. Crit Care Med 34:2835–2841PubMedCrossRef
128.
Novak KR, Nardelli P, Cope TC et al (2009) Inactivation of sodium channels underlies reversible neuropathy during critical illness in rats. J Clin Invest 119:1150–1158PubMedPubMedCentralCrossRef
129.
Rezaiguia-Delclaux S, Lefaucheur JP, Zakkouri M et al (2002) Severe acute polyneuropathy complicating orthotopic liver allograft failure. Transplantation 74:880–882PubMedCrossRef
130.
Rich MM, Pinter MJ (2003) Crucial role of sodium channel fast inactivation in muscle fibre inexcitability in a rat model of critical illness myopathy. J Physiol 547(2):555–566PubMedPubMedCentralCrossRef
131.
Schattschneider J, Wasner G, Baron R (2001) Zytostatikainduzierte Polyneuropathien. Aktuelle Neurologie 28:53–61CrossRef
132.
Segredo V, Caldwell JE, Matthay MA et al (1992) Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med 327:524–528PubMedCrossRef
133.
Tennilä A, Salmi T, Pettilä V et al (2000) Early signs of critical illness polyneuropathy in ICU patients with systemic inflammatory response syndrome or sepsis. Intensive Care Med 26:1360–1363PubMedCrossRef
134.
van den Berghe G, Wilmer A, Hermans G et al (2006) Intensive insulin therapy in the medical ICU. N Engl J Med 354:449–461PubMedCrossRef
135.
van den Berghe G, Wouters P, Weekers F et al (2001) Intensive insulin therapy in the critically ill patients. N Engl J Med 345:1359–1367PubMedCrossRef
136.
van der Schaaf M, Beelen A, de Vos R (2004) Functional outcome in patients with critical illness polyneuropathy. Disabil Rehabil 26:1189–1197PubMedCrossRef
137.
Williams S, Horrocks IA, Ouvrier RA et al (2007) Critical illness polyneuropathy and myopathy in pediatric intensive care: A review. Pediatr Crit Care Med 8:18–22PubMedCrossRef
138.
Zifko UA (2000) Long-term outcome of critical illness polyneuropathy. Muscle Nerve (Suppl 9):49–52
139.
Abrutyn E, Berlin JA (1991) Intrathecal therapy in tetanus: a meta-analysis. JAMA 266:2262–2267PubMedCrossRef
140.
Ahmadsyah I, Salim A (1985) Treatment of tetanus: an open study to compare the efficacy of procaine penicillin and metronidazole. Br Med J 291:648–650CrossRef
141.
Alpers K, van Treeck U, Frank C (2005) Outbreak of wound botulism in drug useres in Germany, October-December 2005. Euro Surveill 10:E051215.4PubMed
142.
Anandaciva S, Koray CW (1996) Tetanus and rocuronium in the intensive care unit. Anesthesia 5:879–881
143.
Arnon SS, Schlechter R, Ingelsby TV et al (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA 285:1059–1070PubMedCrossRef
144.
Arnon SS (2002) Clinical botulism. In: Brin MF, Hallet M, Jancovic J (Hrsg) Scientific and therapeutic aspects of botulinum toxin. Lipincott Williams, Philadelphia, S 145–150
145.
Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL (2006) Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 354:445–447CrossRef
146.
Behring E, Kitasato S (1890) Über das Zustandekommen der Diphtherie-Immunität und der Tetanus Immunität bei Thieren. Dtsch Med Wochenschr 16:1027–1049
147.
Bleck TP, Brauner S (1997) Tetanus. In: Scheld WM, Whitley RJ, Durack DT (Hrsg) Infections of the central nervous system, 2. Aufl. Lipinscott-Raven, Philladelphia, S 629–653
148.
Brett MM, Hallas G, Mpamugo O (2004) Wound botulism in the UK and Ireland. J Med Microbiol 53:555–561PubMedCrossRef
149.
150.
Chertow DS, Tan ET, Maslanka SE et al (2006) Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA 296:2476–2479PubMedCrossRef
151.
152.
Domenighetti GM, Savary S, Striker H (1984) Hyperadrenergic syndrome in severe tetanus responsive to labetalol. Br Med J 288:1483–1484CrossRef
153.
Duning T, Schabitz WR (2007) Die Behandlung des Tetanus. Nervenarzt 98:145–155CrossRef
154.
Farrer JJ, Yen LM, Cook T (2000) Tetanus. J Neurol Neurosurg Psychiatry 332:761–766
155.
Fenicia L, Franciosa G, PourshabanM et al (1999) Intestinal toxemia botulism in two young people, caused by Clostridium butyricum Type E. Clin Infect Dis 29:1381–1387PubMedCrossRef
156.
Gupta PS, Kapoor R, Goyal S et al (1980) Intrathecal human tetanus immue globulin in early tetanus. Lancet 2:439–440PubMedCrossRef
157.
Meunier FA, Herreros J, Schiavo G et al (2002) Molecular mecahnisms of action of botulinal neurotoxins and the synaptic remodelling they induce in vivo at the skeletal neuromuscular junction. In: Massero EJ (Hrsg) Handbook of neurotoxicology, Bd. I. Humana Press, Totowa, New Jersey, S 305–347
158.
159.
Mezaki T, Kaji R, Kohara N et al (1996) Development of general weakness in a patient with amyotrophic lateral sclerosis after focal botulinum toxin injection. Neurology 46:845–846PubMed
160.
Müller H, Börner U, Ziersky J et al (1987) Intrathecal baclofen therapy for tetanus induced spasticity. Anesthesiology 66:76–79PubMedCrossRef
161.
Nicolaier A (1884) Über infectiösen Tetanus. Dtsch Med Wochenschr 10:842–844CrossRef
162.
Passaro DJ, Werner SB, McGee J et al (1998) Wound botulism associated with black tar heroin among injecting drug users. JAMA 279:859–863PubMedCrossRef
163.
Salmaso S (1999) Special issue on botulism. European communicable disease bulletin 4:1–16
164.
Schiavo G, Rosetto O, Tonello F et al (1995) Intracellular targets and metalloprotease activity of tetanus and botulinum toxin neurotoxins. Curr Top Microbiol Immunol 195:257–274PubMed
165.
Schmidt RD, Schmidt TW (1992) Infant botulism: a case series and review of the literature. J Emerg Med 10:763–772CrossRef
166.
167.
Thwaites CL, Yen LM, Loan HT et al (2006) Magnesium sulphate for treatment of severe tetanus: a randomised controlled trial. Lancet 368:1398–1389CrossRef
168.
169.
Almeida C, Coutinho E, Moreira D, Santos E, Aguiar J (2010) Myasthenia gravis and pregnancy: anesthetic management – a series of cases. Eur J Anaesthesiol 27:985–990PubMedCrossRef
170.
Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ (2009) Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 72:1548–54PubMedCrossRef
171.
Baggi F, Andreeta F, Maggi L et al (2013) Complete stable remission and autoantibody specificity in myasthenia gravis. Neurology 80:188–195PubMedCrossRef
172.
173.
Ciafaloni E, Nikhar NK, Massey JM, Sanders DB (2000) Retrospective analysis of the use of ciclosporine in myasthenia gravis. Neurology 55:448–450PubMedCrossRef
174.
Collongues N, Casez O, Lacour A et al (2012) Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study. Muscle Nerve 46:687–691PubMedCrossRef
175.
Diaz-Manera J, Martinez-Hernandez E, Querol L et al (2012) Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 78:189–193PubMedCrossRef
176.
Ferrero S, Pretta S, Nicoletti A, Petrera P, Ragni N (2005) Myasthenia gravis: management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol 121:129–138PubMedCrossRef
177.
Gajdos P, Chevret S, Toyka K (2008) Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2008 CD002277
178.
Gold R, Toyka KV (2007) Immuntherapie neurologischer Erkrankungen, 2.. Aufl. Uni-Med, Bremen
179.
Harper CM (1999) Electrodiagnosis of end plate disease. In: Engel AG (Hrsg) Myasthenia gravis and Myasthenic Disorders. Oxford, Oxford University Press, S 65–84
180.
Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A (2001) Autoantibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nature Med 7:365–368PubMedCrossRef
181.
Jarius F, Paul F, Franciotta D et al (2012) Neuromyelitis optica spectrum disorders in patients with myasthenia gravis. Mult Scler 18:1135–1143PubMedCrossRef
182.
Kalita J, Kohat AC, Misra UK (2014) Predictors of outcome of myasthenic patients. Neurol Sci 35:1109–1114PubMedCrossRef
183.
184.
Köhler W, Bucka C, Klingel R (2011) A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis. J Clin Apher 26:347–355PubMedCrossRef
185.
Leuzzi G, Meacci E, Cusumano G, Cesario A, Chiapetta M et al (2014) Thymectomy in myasthenia gravis: proposal for a predictive score of postoperative myasthenic crisis. Eur J Cardiovasc Surg 45:e76–88CrossRef
186.
Liu JF, Wang WX, Xue J et al (2010) Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis. Ther Apher Dial 14:153–160PubMedCrossRef
187.
Maselli RA, Ellis W, Mandler RN (1997) Cluster of wound botulism in california: clinical, electrophysiologic, and pathologic study. Muscle Nerve 20:1284–1295PubMedCrossRef
188.
McGrogan A, Sneddon S, deVries CS (2010) The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology 34:171–183PubMedCrossRef
189.
Merrigioli MN, Ciafaloni E, Al-Hayk KA et al (2009) Mycophenolate mofetil for myasthenia gravis: an analysis of efficiacy, safety and tolerability. Neurology 61:1438CrossRef
190.
Minami N, Fujiki N, Doi S et al (2011) Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis. J Neurol Sci 300:59–62PubMedCrossRef
191.
Müllges W (2013) Respiratorentwöhnung aus Sicht der Neurologie. AINS 48:616–620PubMed
192.
Müllges W, Toyka KV (1997) Akute Muskelschwäche – Differentialdiagnose und Therapie neuromuskulärer Krankheiten. Intensivmedizin und Notfallmedizin 34:110–123CrossRef
193.
Müllges W, Stoll G (2009) Intensivmedizinische Probleme bei neuromuskulärern Krankheiten. Intensivmed up2date 5:209–228CrossRef
194.
Müllges W, Stoll G (2010) Akuttherapie des Guillain-Barré-Syndroms und der myasthenen Krise. Akt Neurol 37:474–484CrossRef
195.
Müllges W, Gold R, Toyka KV (2003) Myasthene Krise. Intensivmedizin und Notfallmedizin 40:111–123CrossRef
196.
Pakzad Z, Aziz T, Oger J (2011) Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada. Neurology 76:1526–1528PubMedCrossRef
197.
Palace J, Newsom Davis J, Lecky B (1998) A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 50:1778–1783PubMedCrossRef
198.
Pascuzzi RM (2001) Pearls and pitfalls in the diagnosis and management of neuromuscular junction disorders. Semin Neurol 21:425–440PubMedCrossRef
199.
Pasnoor M, Wolfe GI, Nations S et al (2010) Clinical findings in MuSK antibody positive myasthenia gravis. Muscle Nerve 41:370–374PubMedCrossRef
200.
Quereshi AI, Choudry MA, Akbar MS et al (1999) Plasma exchange versus immunoglobulin treatment in myasthenic crisis. Neurology 52:629–632CrossRef
201.
Sanders DB, Massey JM, Sanders LL, Edwards LJ (2000) A randomized trial of 3,4-diaminopyridine in lambert-eaton myasthenic syndrome. Neurology 54:603–607PubMedCrossRef
202.
Schneider-Gold C, Müllges W (2011) Muskelkrankheiten auf der Intensivstation. Intensivmedizin up-2-date 7:233–246CrossRef
203.
Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR (2005) Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev CD 002828
204.
Schönhofer B, Weber-Carstens S, Müllges W (2012) Entwöhnung von der Beatmung unter besonderer Berücksichtigung des prolongierten Weaning. DIVI 3:166–173
205.
Schröder A, Linker RA, Gold R (2009) Plasmapheresis for neurological disorders. Expert Rev Neurother 9:1331–1339PubMedCrossRef
206.
Seneviratne J, Mandrekar J, Wijdicks EFM, Rabinstein AA (2008) Noninvasive ventilation in myasthenic crisis. Arch Neurol 65:54–58PubMed
207.
Sieb JP (2013) Myasthenia gravis: an update for the Clinician. Clin Experiment Immunol 175:408–418CrossRef
208.
209.
Smith AG, Wald J (1996) Acute ventilatory failure in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine. Neurology 46:1143–1145PubMedCrossRef
210.
Spillane J, Hayward M, Hirsch NP, Taylor C, Kullmann DM, Howard RS (2013) Thymectomy: role in the treatment of myasthenia gravis. J Neurol 260:1798–1801PubMedCrossRef
211.
Spillane J, Hirsch NP, Kullmann DM, Taylor C, Howard JS (2014) Myasthenia gravis – treatment of acute severe exacerbations in the intensive care unit results in favourable long-term prognosis. Eur J Neurol 21:171–173PubMedCrossRef
212.
213.
Suzuki S, Utsugisawa K, Yoshikawa H et al (2009) Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol 66:1334–1338PubMedCrossRef
214.
Tindall RS (1987) Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 316:719–724PubMedCrossRef
215.
Vincent A, Drachman B (2002) Myasthenia gravis. Adv Neurol 88:159–188PubMed
216.
Wu JY, Kuo PH, Fan PC et al (2009) The role of non-invasive ventilation and factors predicting extubation outcome in myasthenic crisis. Neurocrit Care 10:35–42PubMedCrossRef
217.
Zhang B, Tzartos JS, Belimezi M et al (2012) Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 69:445–451PubMedCrossRef
218.
Zinman L, Ng E, Bril V (2007) IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 68:837–841PubMedCrossRef
Metadaten
Titel
Neuromuskuläre Erkrankungen
verfasst von
Wolfgang Müllges, Prof. Dr.
Ralf Gold, Prof. Dr.
Hans-Christian Hansen, Prof. Dr.
Martin Anetseder, Prof. Dr.
Thomas Metterlein, PD Dr.
Clemens R. Müller, Prof. Dr. rer. nat.
Ernst Hund, Prof. Dr.
Martin Winterholler, PD Dr.
Copyright-Jahr
2015
Verlag
Springer Berlin Heidelberg
Buch
NeuroIntensiv

Print ISBN: 978-3-662-46499-1

Electronic ISBN: 978-3-662-46500-4

Copyright-Jahr: 2015

DOI
https://doi.org/10.1007/978-3-662-46500-4_37

Neu im Fachgebiet AINS

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Leitsymptom Rückenschmerzen | Nachrichten

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Stereotaktische Radiatio schlägt konventionelle Bestrahlung
weitere anzeigen

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren